Solid Biosciences Plunges 10.64% Amid Mixed Earnings Outlook

On June 16, 2025, Solid Biosciences experienced a significant drop of 10.64% in pre-market trading, reflecting a notable decline in investor sentiment.

Solid Biosciences, a biotechnology company focused on developing therapies for neuromuscular and cardiac diseases, has seen a mixed outlook from analysts. The company's earnings are projected to improve slightly from ($2.84) to ($2.63) per share in the coming year. However, the stock has faced challenges, with a consensus rating of "Buy" and an average target price of $14.90, indicating a potential upside of 230.38%.

Several institutional investors have recently adjusted their positions in Solid Biosciences. Bank of America Corp DE increased its holdings by 87.9%, while other investors such as Rhumbline Advisers, Quantum Private Wealth LLC, American Century Companies Inc., Sei Investments Co., and Prudential Financial Inc. also boosted their stakes. These moves suggest a continued interest in the company despite recent market volatility.

Analysts have provided varied opinions on the stock. JMP Securities reiterated a "market outperform" rating with a $15.00 price target, while Chardan Capital set a "buy" rating with a $15.00 price target. JPMorgan Chase & Co. and HC Wainwright also issued positive ratings, with price targets ranging from $11.00 to $20.00. However, Wedbush decreased its price target to $17.00, reflecting some caution among analysts.

Solid Biosciences' lead product candidate, SGT-003, is a gene transfer candidate for the treatment of Duchenne muscular dystrophy, and SGT-501 is aimed at treating Catecholaminergic polymorphic ventricular tachycardia. The company's focus on gene therapy shows promise amid competition in the field, which could influence future stock performance.